Table 5.
Induction Antifungal Therapy Among Patients With Cryptococcosis
| Antifungal Therapy (All Sites) | Total (N = 709) | Cryptococcus neoformans (n = 452) |
Cryptococcus gattii
(n = 257) |
P Value |
|---|---|---|---|---|
| Any AmBd | 291 (41.0) | 201 (44.5) | 90 (35.0) | .0014 |
| Any L-AmB | 227 (32.0) | 144 (31.9) | 83 (32.3) | .90 |
| Any flucytosine | 361 (50.9) | 250 (55.3) | 111 (43.2) | .0019 |
| Any AmB plus flucytosine | 358 (50.5) | 248 (54.9) | 110 (42.8) | .0020 |
| AmBd plus flucytosine | 224 (31.6) | 160 (35.4) | 64 (24.9) | .0039 |
| L-AmB plus flucytosine | 156 (22.0) | 90 (19.9) | 66 (25.7) | .075 |
| Any CNS cryptococcosis | (n = 419) | (n = 291) | (n = 128) | |
| Any AmBd | 251 (59.9) | 175 (60.1) | 76 (59.4) | .88 |
| Any L-AmB | 179 (42.7) | 115 (39.5) | 64 (50) | .046 |
| Any flucytosine | 320 (76.4) | 226 (77.7) | 94 (73.4) | .35 |
| Any AmB plus flucytosine | 320 (76.4) | 226 (77.7) | 94 (73.4) | .35 |
| AmBd plus flucytosine | 203 (48.5) | 147 (50.5) | 56 (43.8) | .20 |
| L-AmB plus flucytosine | 137 (32.7) | 81 (27.8) | 56 (43.8) | .0014 |
| Duration of induction (all sites) | (n = 473) | (n = 331) | (n = 142) | |
| 1 wk (1–9 d) | 100 (21.1) | 76 (23.0) | 24 (16.9) | <.0001 |
| 2 wk (10–20 d) | 240 (50.7) | 186 (56.2) | 54 (38.0) | |
| 4–6 wk (21–49 d) | 107 (22.6) | 62 (18.7) | 45 (31.7) | |
| ≥7 wk (50–90 d) | 26 (5.5) | 7 (2.1) | 19 (13.4) |
Data are presented as No. (%) unless otherwise indicated. Analysis of variance or Wilcoxon rank-sum testing and χ 2 or Fisher exact tests were used to compare continuous and categorical variables, respectively.
Abbreviations: AmB, amphotericin B (includes deoxycholate and lipid formulations); AmBd, amphotericin B deoxycholate; CNS, central nervous system; L-AmB, lipid formulation of amphotericin B.